Athena Therapeutics Announces Initial Financing From HighCape Capital And Connecticut Innovations Share Article NEW HAVEN, Conn. (PRWEB) December 17, 2020 Athena Therapeutics today announced the closing of an initial financing round with HighCape Capital and Connecticut Innovations. This round of funding will provide the necessary resources to create an innovative cancer drug company that combines world-class scientists, powerful intellectual property, support from Yale University, and a leadership team with extensive experience building successful life sciences companies. Utilizing discoveries and intellectual property licensed from Yale, Athena will focus on exploiting unique metabolic defects in cancer with the goal of developing transformative therapeutics to treat various forms of cancer.